Organ-Sparing Strategy ‘Promising’ in Muscle-Invasive Bladder Cancer

(MedPage Today) — SAN FRANCISCO — Perioperative sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) achieved a “promising” clinical complete response rate, as well as bladder preservation, in nearly 40% of patients with muscle-invasive…